Neuronetics, Inc.

Stage 2 · Advancing · week 11

As of Oct 22, 2026, Neuronetics is in Stage 2, the uptrend phase, now in week 11 (since Aug 11, 2026). It closed at $2.08, 37.0% below its 52-week high and above its 200-day average, which is rising.

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. More about the company

$2.08

+3.48% today

$158M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is STIM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 18w

S4 20w

S2 15w

S4 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 5w → S2 18w → S3 6w → S4 20w → S1 11w → S2 15w → S3 12w → S2 2w → S3 5w → S4 19w → S1 3w → S4 9w → S1 5w → S4 7w → S1 2w → S2 10w current

Total tracked: 166 weeks across 17 stage runs.

STIM among Medical Devices68th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…68	STIMNeuronetics, Inc.	Stage 2 · wk 11	35	−27.8%

vs 52W High

-37.0%

$1.18 lo$3.30 hi

37.0% below 52W high, far from high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 11

1w13w26w

Week 11, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

11.7%

200 DMA: $1.86 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.66x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-27.8%

+20.2%

+23.1%

YTD

+44.4%

-27.8%

Scan Membership

Breakout Watch

Latest: 2025-02-03

6 appearances in last 60 days. First seen: 2020-08-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 11 · Vol 0.66x

2026-10-21S2

Wk 11 · Vol 0.16x

2026-10-20S2

Wk 10 · Vol 0.33x

2026-10-19S2

Wk 10 · Vol 0.31x

2026-10-16S2

Wk 10 · Vol 0.53x

2026-10-15S2

Wk 10 · Vol 0.42x

2026-10-14S2

Wk 10 · Vol 0.44x

2026-10-13S2

Wk 9 · Vol 0.29x

2026-10-12S2

Wk 9 · Vol 0.17x

2026-10-09S2

Wk 9 · Vol 0.30x

2026-10-08S2

Wk 9 · Vol 0.34x

2026-10-07S2

Wk 9 · Vol 0.33x

Moving averages & range

50 DMA

$2.63

200 DMA

$1.86

52W High

$3.30

52W Low

$1.18

5D Low

$1.89

Resistance levels (recent highs)

20d High

$2.74

60d High

$3.30

120d High

$3.30

250d High

$3.30

Next resistance

+31.7%

to 20d High

ROE

-116.1%

Profit margin -19.6%

Dividend Yield

0.00%

P/B 8.9

Neuronetics: quick answers

What stage is Neuronetics in?

As of Oct 22, 2026, Neuronetics (STIM) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 11, 2026 and is in week 11. What the four stages mean

Is Neuronetics in an uptrend?

Yes. Neuronetics is in a Stage 2 uptrend. It trades 11.7% above its 200-day average, which is rising.

How far is Neuronetics from its 52-week high?

Neuronetics closed at $2.08 on Oct 22, 2026, 37.0% below its 52-week high of $3.30. Its 52-week low is $1.18.

How has Neuronetics performed over the past year?

As of Oct 22, 2026, Neuronetics is down 27.8% over the past year and up 44.4% so far in 2026.

Which sector and industry is Neuronetics in?

Neuronetics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.